The company made this announcement after market hours on Thursday, 12 November 2009.
Meanwhile, the BSE Sensex was up 32.16 points, or 0.19%, to 16,728.19.
On BSE, 4,882 shares were traded in the counter as against an average daily volume of 5.53 lakh shares in the past one quarter.
The stock hit a high of Rs 416.90 and a low of Rs 411 so far during the day. The stock had hit a 52-week high of Rs 426.85 on 9 November 2009 and a 52-week low of Rs 133.15 on 12 March 2009.
The large-cap stock had outperformed the market over the past one month till 12 November 2009, rising 4.55% as compared to the Sensex's 1.94% fall. It had also outperformed the market in the past one quarter, surging 42.39% as compared to the Sensex's return of 11.16%.
The company's equity capital is Rs 210.21 crore. Face value per share is Rs 5.
The current price of Rs 416 discounts the company's Q3 September 2009 annualized EPS of Rs 17.71, by a PE multiple of 23.49.
A pre-qualification for a drug from the World Health Organization (WHO) acts as a guide to United Nations agencies and countries that select suppliers for drugs.
In early October 2009, European Union officials raided Ranbaxy's French unit as part of an investigation of generic drug practices. The European Commission officials launched anti-trust investigations against alleged restrictive trade practices by pharma companies.
In September 2009, Ranbaxy Laboratories entered into a strategic in-licensing agreement with Medy-Tox Inc of South Korea, for selling a cosmetic product in India. Ranbaxy said it will launch Medy-Tox's anti-ageing medicine Neuronox in India to boost its presence in the dermatological segment.
Neuronox is the most effective anti-ageing medicine and is much superior to the available therapy options. The current market size for the drug, in India, is approximately Rs 30 crore per annum.
South Korea-based Medy-Tox is specialized in doing research in clostridium botulinum toxins and related products.
Ranbaxy Laboratories reported net profit of Rs 186.08 crore in Q3 September 2009 as compared to net loss of Rs 352.93 crore in Q3 September 2008. Net sales rose 3.8% to Rs 1189.60 crore in Q3 September 2009 over Q3 September 2008.
Ranbaxy Laboratories manufactures and markets, generic pharmaceuticals, value added generic pharmaceuticals, branded generics, active pharmaceuticals and intermediates.